Efficacy of Irinotecan and Capecitabine Versus(vs) Cisplatin and Capecitabine in Patients With Esophago-Gastric Cancer

Johannes Gutenberg University Mainz120 enrolled

Overview

The purpose of this study is to determine which Arm (capecitabine + irinotecan versus capecitabine + cisplatin) shows higher response rates in the treatment of advanced gastric-oesophagal cancer Furthermore, comparison of progression-free survival, 1-year survival, Quality of Life and safety

capecitabine + irinotecan versus capecitabine + cisplatin, as published by Kang et al. (ASCO 2006)

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

120

Conditions

Gastric Cancer

Interventions

Cisplatin, Irinotecan, CapecitabineDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * gastric or gastric-oesophagal junction adenocarcinoma * unidimensional measurable disease * Karnofsky index \>/=60% Exclusion Criteria: * prior chemo- or radiotherapy * colorectal diseases * brain metastases

Locations (1)

Johannes Gutenberg Universität , I. Medizinische Klinik und Polokilinik

Mainz, Germany

Outcomes

Primary Outcomes

response rate

Secondary Outcomes

safety

progression free survival

1 year survival

Quality of Life

Analysis of the dose and efficacy of Epoetin beta weekly in anaemic patients

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.